ESTRO 2024 - Abstract Book

S2297

Clinical - Urology

ESTRO 2024

200

Poster Discussion

PSMA-PET/CT improves outcomes after salvage radiotherapy for recurrent prostate cancer after surgery

Constantinos Zamboglou 1,2 , Paulina Staus 3 , Martin Wolkewitz 3 , Jan C. Peeken 4,5,6 , Marco Vogel 4,7,6 , Konstantinos Ferentinos 1 , Iosif Strouthos 1 , Andrea Farolfi 8 , Stefan A. Koerber 9 , Alexis Vrachimis 10,11 , Simon K. B. Spohn 12,13 , Mohamed Shelan 14 , Anca-Ligia Grosu 12,15 , Stephanie G.C. Kroeze 16 , George Hruby 17 , Alessio G. Morganti 18 , Thomas Wiegel 19 , Louise Emmett 20 , Stefano Fanti 8 , Matthias Guckenberger 21 , Stefanie Hayoz 22 , Claus Belka 23 , Daniel M. Aebersold 14 , Nina-Sophie Schmidt-Hegemann 23 , Pirus Ghadjar 24 1 German Oncology Center, Radiation Oncology, Limassol, Cyprus. 2 Medical Center - University of Freiburg, Radiation Oncology, Freiburg, Germany. 3 Medical Center - University of Freiburg, Institute of Medical Biometry and Statistics, Division Methods in Clinical Epidemiology, Freiburg, Germany. 4 Klinikum rechts der Isar, Technical University of Munich (TUM), Radiation Oncology, Munich, Germany. 5 adiation Medicine (IRM), Radiation Sciences (DRS), Munich, Germany. 6 Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Bologna, Italy. 7 Radiation Medicine (IRM), Radiation Sciences (DRS), Munich, Germany. 8 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, Italy. 9 Krankenhaus Barmherzige Brüder Regensburg, Radiation Oncology, Regensburg, Germany. 10 German Oncology Center, Nuclear Medicine, Limassol, Cyprus. 11 C.A.R.I.C, Cancer Research and Innovation Center, Limassol, Cyprus. 12 Medical Center – University of Freiburg, Radiation Oncology, Freiburg, Germany. 13 Medical Center – University of Freiburg, Berta-Ottenstein-Programme, Freiburg, Germany. 14 Inselspital, Bern University Hospital and University of Bern, Radiation Oncology, Bern, Switzerland. 15 German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. 16 Cantonal Hospital Aarau, Radiation Oncology KSA KSB, Aarau, Switzerland. 17 Royal North Shore Hospital - University of Sydney, Radiation Oncology, Sydney, Australia. 18 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Radiation Oncology, Heidelberg, Germany. 19 University of Ulm, Radiation Oncology, Ulm, Germany. 20 St Vincent’s Hospital Sydney, Theranostics and Nuclear medicine, Sydney, Australia. 21 University Hospital Zurich, University of Zurich, Radiation Oncology, Zurich, Switzerland. 22 SAKK, Competence Center, Bern, Switzerland. 23 University Hospital, LMU Munich, Radiation Oncology, Munich, Germany. 24 Charité - Universitätsmedizin Berlin, Radiation Oncology, Berlin, Germany

Purpose/Objective:

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) for prostate cancer patients with prostate specific antigen (PSA) persistence or relapse after prostatectomy. Whether the implementation of PSMA-PET is leading to improved outcomes in these patients is not answered yet.

Material/Methods:

Patients who underwent sRT from two separate patient cohorts were included. The control cohort consists of 344 patients from the randomized-controlled phase III SAKK 09/10 trial (28 hospitals, three countries, no PSMA-guided sRT). The PSMA-PET guided cohort consists of 1548 patients from a retrospective multicenter cohort (11 hospitals, 5 countries, PSMA-guided sRT). Inclusion criteria for both studies were adapted. Patients younger 48 or older 75, with positive lymph nodes in primary surgery, initial cM1 status, cM1 status on PET imaging, PSA>0.5 ng/ml and with